Solid Tumor Testing Solutions

Sequanta provides comprehensive genomic profiling solutions for solid tumor biomarker testing, covering tissue testing, liquid biopsy, and MRD dynamic monitoring.

FoundationOne CDx Series -

Foundationone CDx (F1CDx) and Foundationone Liquid CDx (F1 Liquid CDx) are FDA-approved tumor NGS large-panel companion diagnostic products. They detect 324 genes along with immunotherapy biomarkers such as MSl-H/dMMR and TMB, and have become the standard testing methods for international multi-center clinical trials.

TSO500 Series

TSO500 (TruSight Oncology 500) is a pan-cancer NGS testing product launchedby Illumina. Through a single test, it can simultaneously analyze 523 DNA genes and 55 RNA genes, detecting variants such as SNVs, Indels, CNVs, and genefusions, while calculating TMB, MSI, and HRD biomarkers. This provides acomprehensive genomic analysis solution for the precision diagnosis andtreatment of solid tumors.

OncoCODE769 Series

Based on the NGS platform, this panel includes 769 critical pathway genes related to tumor occurrence, development, and treatment,. It conducts detections for Single Nucleotide Variants (SNV), Insertions/Deletions (INDEL), Fusions (FUSION), Copy Number Variations (CNV), Tumor Mutational  Burden (TMB), Microsatellite Instability (MSI), and Human Leukocyte Antigen  (HLA) Class mInolecule genotyping.

Solid Tumor MRD

Detecting circulating tumor DNA (ctDNA) for Molecular Residual Disease (MRD) after surgery or the completion of standard systemic therapy can indicate poor prognosis and screen for high-risk recurence populations. Incorporating ctDNA endpoints into prospective randomized clinical trials is essentlal for furthergenerating evidence to support the regulatory and clinical application of ctDNA.